SITC 2024 Poster 84
A High-Content Screening Platform for Testing Immunotherapies in 100 Patient-Derived Organoid Models
Saskia de Man, Sergei Chavez Abiega, Tomas Veenendaal, Michelle Kop, Jarmil Hanrath, Daniel Okkes, Emma Spanjaard, Leo Price1, Gera Goverse
This research details the innovative approach of Crown Bioscience's high-content screening platform, designed to evaluate immunotherapies across a wide range of cancer models using patient-derived organoids (PDOs).
This groundbreaking technology enables more accurate predictions of therapeutic efficacy, leveraging advanced imaging and co-culture systems to provide insights into immune response across various cancer types. Explore the potential of this platform to accelerate immunotherapy research by enabling comprehensive and scalable in vitro testing.
Download this Poster to Discover:
- Platform Overview: Understand the high-content imaging and analysis platform specifically tailored for 3D organoid co-cultures.
- Study Design and Methods: Get insights into how patient-derived and PDX-derived organoids were used alongside immune cells for rigorous testing.
- Screening Across Cancer Types: Learn how 100 organoid models from diverse cancer indications were screened, providing a broad perspective on therapeutic sensitivity.
- Immune Response Insights: Discover the findings on T cell engagers and cellular therapies when co-cultured with organoids, offering a deep dive into immune cell infiltration and cytokine production.
- High-Resolution Imaging Techniques: Explore the high-resolution 3D imaging processes used for analysis, enabling detailed visualizations of cell interactions and therapeutic effects.
- Results & Impact: Review the key results that illustrate the efficacy of different immunotherapy strategies, including CAR-T and EGFR targeting, in simulated tumor environments.
- Clinical Relevance: Understand the implications of these findings in predicting therapeutic outcomes and advancing personalized cancer treatments.
Download the Poster Now!
